Eli Lilly’s Kisunla Approved in China, Paving the Way for Innovative Alzheimer’s Treatment Options
China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The treatment, designed to slow memory decline and clear brain plaques, offers early-stage patients a
Lilly's Alzheimer's drug Kisunla is cleared in China
China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there almost a year after Eisai and Biogen's anti-amyloid rival Leqembi (lecanemab), which was cleared by the NMPA in January.
Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...
Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...
Biogen (BIIB) closed near a 52-week low of $150.03. The stock trades at a discount because the biotech firm lacks growth ...
Australia's corporate watchdog on Wednesday said it has sued trading platform Binance Australia Derivatives, alleging that ...
BofA reinstated coverage of Biogen (BIIB) with a Neutral rating and $178 price target Biogen is “a cheaper name,” mostly ...
Biogen Inc. (NASDAQ:BIIB), currently trading near its 52-week low at $156.19, finds itself at a critical juncture as it navigates the launch of its Alzheimer's treatment Leqembi while grappling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback